威尔药业
(603351)
| 流通市值：32.64亿 | | | 总市值：32.64亿 |
| 流通股本：1.35亿 | | | 总股本：1.35亿 |
| 利润表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 营业总收入 | 356,303,724.13 | 1,335,037,035.4 | 1,018,241,707.95 | 673,722,955.67 |
| 营业总成本 | 313,328,245.76 | 1,170,622,101.96 | 892,228,158.27 | 588,979,381.47 |
| 其他经营收益 | | | | |
| 营业利润 | 43,926,078.24 | 173,090,592.8 | 133,921,847.46 | 85,951,118.51 |
| 利润总额 | 43,922,396.32 | 172,644,892.95 | 133,579,515.57 | 85,856,645.49 |
| 净利润 | 36,847,997.32 | 148,987,071.3 | 111,738,699.49 | 71,302,630.46 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 36,847,997.32 | 148,987,071.3 | 111,738,699.49 | 71,302,630.46 |
| 资产负债表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 流动资产: | | | | |
| 流动资产合计 | 959,948,713.04 | 906,146,316.7 | 895,190,555.3 | 791,592,373.74 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,668,242,429.89 | 1,687,704,748 | 1,690,267,503.14 | 1,700,938,485.99 |
| 资产总计 | 2,628,191,142.93 | 2,593,851,064.7 | 2,585,458,058.44 | 2,492,530,859.73 |
| 流动负债: | | | | |
| 流动负债合计 | 691,181,892.34 | 695,660,677.66 | 696,492,730.52 | 668,393,125.94 |
| 非流动负债: | | | | |
| 非流动负债合计 | 96,119,497.51 | 95,345,318.87 | 122,819,269.98 | 98,817,892.39 |
| 负债合计 | 787,301,389.85 | 791,005,996.53 | 819,312,000.5 | 767,211,018.33 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,834,293,618.94 | 1,795,462,891.48 | 1,759,108,706.25 | 1,720,509,672.33 |
| 股东权益合计 | 1,840,889,753.08 | 1,802,845,068.17 | 1,766,146,057.94 | 1,725,319,841.4 |
| 负债和股东权益合计 | 2,628,191,142.93 | 2,593,851,064.7 | 2,585,458,058.44 | 2,492,530,859.73 |
| 现金流量表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 255,497,258.75 | 1,155,133,797.6 | 845,619,734.19 | 540,300,302.45 |
| 经营活动现金流出小计 | 238,299,273.4 | 916,888,862.01 | 701,839,536.43 | 466,025,685.03 |
| 经营活动产生的现金流量净额 | 17,197,985.35 | 238,244,935.59 | 143,780,197.76 | 74,274,617.42 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 100,000 | 14,123,611.04 | 915,380.18 | 900,000 |
| 投资活动现金流出小计 | 19,125,404.08 | 88,179,557.37 | 83,082,846.97 | 72,797,235.08 |
| 投资活动产生的现金流量净额 | -19,025,404.08 | -74,055,946.33 | -82,167,466.79 | -71,897,235.08 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 200,000,000 | 551,000,000 | 421,000,000 | 309,000,000 |
| 筹资活动现金流出小计 | 186,707,995.23 | 537,696,235.37 | 362,466,257.74 | 304,653,300.15 |
| 筹资活动产生的现金流量净额 | 13,292,004.77 | 13,303,764.63 | 58,533,742.26 | 4,346,699.85 |
| 汇率变动对现金及现金等价物的影响 | -1,868,455.15 | -828,047.87 | 780.95 | 342,762.81 |
| 现金及现金等价物净增加额 | 9,596,130.89 | 176,664,706.02 | 120,147,254.18 | 7,066,845 |
| 期末现金及现金等价物余额 | 433,461,319.29 | 423,865,188.4 | 367,347,736.56 | 254,267,327.38 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 176,664,706.02 | - | 7,066,845 |
最新报告期：2026-05-12| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 申万宏源 | 张静含 | 1.27 | 1.43 | 1.59 | 2026-05-12 |